Date: 2016-04-04
Type of information: Financing round
Company: Anergis (Switzerland)
Investors:
Amount: CHF 5 Million
Funding type: financing round
Planned used:
- Anergis is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel, ultra-fast proprietary allergy immunotherapy products for the most prevalent allergies. The Company is preparing a Phase IIb clinical trial with its lead compound AllerT in patients with birch pollen allergy. The study is designed as a multicenter, double-blind, placebocontrolled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT In Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis (ATIBAR).
- This trial is expected to start in fall 2016. With a total of 450 patients, ATIBAR will be the largest field-based trial conducted so far with an ultra-fast allergy treatment for tree allergy. The trial is designed as a confirmatory efficacy trial with the statistical power necessary to meet both European and FDA efficacy criteria for allergy immunotherapy products. Results will be expected in the third quarter of 2017.
Others:
- • On April 4, 2016, Anergis announced that it has closed a CHF 5 million financing round extension with existing investors.
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Is general: Yes
